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http://dx.doi.org/10.1016/j.ccell.2015.07.001SUMMARYNearly 50% of human malignancies exhibit unregulated RAS-ERK signaling; inhibiting it is a valid strategy for
antineoplastic intervention. Upon activation, ERK dimerize, which is essential for ERK extranuclear, but not
for nuclear, signaling. Here, we describe a small molecule inhibitor for ERK dimerization that, without
affecting ERK phosphorylation, forestalls tumorigenesis driven by RAS-ERK pathway oncogenes. This com-
pound is unaffected by resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus,
ERK dimerization inhibitors provide the proof of principle for two understudied concepts in cancer therapy:
(1) the blockade of sub-localization-specific sub-signals, rather than total signals, as a means of impeding
oncogenic RAS-ERK signaling and (2) targeting regulatory protein-protein interactions, rather than catalytic
activities, as an approach for producing effective antitumor agents.INTRODUCTION
The signaling pathway connecting RAS guanosine triphospha-
tases and mitogen-activated protein kinases ERK1 and ERK2
(ERK) is essential for the regulation of cellular proliferation andSignificance
Nearly 50% of human cancers exhibit unregulated signaling th
aberrant flux through this route are attractive options for antit
role in ERK’s extranuclear functions but not its nuclear functi
dimerization that impedes tumorigenesis driven by RAS-ERK
sub-localization-specific sub-signals can be effective for cou
that targeting regulatory protein-protein interactions such as
approach for producing effective antitumor agents.
170 Cancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc.survival (Arozarena et al., 2011). Activatingmutations in constitu-
ents of the RAS-ERK pathway, particularly in members of the
RAS and RAF families, are common in neoplasia, appearing in
nearly 50% of human cancers (Matallanas and Crespo, 2010).
Aberrant flux through the RAS-ERK pathway plays a criticalrough the RAS-ERK pathway. Strategies aimed at reducing
umor therapy. Activated ERK dimerize, playing an essential
ons. Here, we report on a small molecule inhibitor for ERK
pathway oncogenes and demonstrate that the blockade of
nteracting oncogenic RAS-ERK signaling. Our results show
dimerization, rather than catalytic activities, can be a valid
role in the origin, progression, and maintenance of malignancy
(Pylayeva-Gupta et al., 2011). Thus, in the past decades,
academia and industry have devoted colossal efforts to find
drugswherebyoncogenicRAS-ERKsignaling could be curtailed.
The recent years have seen significant advances in the devel-
opment of pharmacological agents directed against the kinases
that populate the RAS-ERK pathway. Compounds inhibiting the
kinase activities of BRAF, MEK, and ERK have yielded promising
preclinical results, and some have progressed to the clinic for the
treatment of some types of tumors, particularly melanoma, with
substantial, though short-lived, success (Montagut and Settle-
man, 2009; Morris et al., 2013). However, an effective and lasting
use of these molecules has been hampered by undesired side
effects and the emergence of drug resistance. Hitherto, most
of the molecular mechanisms leading to the acquisition of resis-
tance to BRAF and MEK inhibitors involve reactivation of ERK
signaling (Little et al., 2013). Therefore, unveiling alternative
mechanisms of action whereby the RAS-ERK pathway could
be targeted and that could avoid such drug-resistance pro-
cesses is highly desirable.
It has long been known that ERK dimerize in response to phos-
phorylation (Khokhlatchev et al., 1998). In this respect, we have
previously shown that ERK dimerization plays an essential role
as an spatial regulator of ERK signals (Calvo et al., 2010) by
specifically orchestrating ERK extranuclear, but not nuclear,
signaling (Casar et al., 2008, 2009). Furthermore, by molecular
biology approaches, we demonstrated that impeding ERK
dimerization, and thereby ERK signals’ extranuclear component,
was sufficient for curtailing cellular transformation and tumor
development (Casar et al., 2008), unveiling ERK dimerization
as an attractive molecular target for the development of antineo-
plastic drugs based on an understudied concept: the disruption
of regulatory protein-protein interactions. Thus, the goal of the
present study was to find small molecules capable of preventing
ERK dimerization.
RESULTS
Characterization of DEL-22379 as an ERK Dimerization
Inhibitor
Detecting ERK dimerization by SDS-PAGE (Philipova and Whi-
taker, 2005) is a delicate technique with a high rate of technical
failures and is therefore unsuitable for screening large numbers
of compounds. Thus, we set up a different procedure: detecting
ERK dimerization by native PAGE electrophoresis, which would
facilitate the process in comparison to the previous assay. This
methodology was validated using ERK dimer and monomer pu-
rification by high-performance liquid chromatography, analytical
centrifugation of ERK monomers and dimers, and molecular
biology approaches, which ascertained that the faster- and
slower-migrating bands in native PAGE electrophoresis corre-
sponded to ERK dimers and monomers, respectively (Figures
S1A–S1C). A higher negative charge and dipole moment for
the dimer, probably as a consequence of the embedding of
charged residues upon dimerization (Table S1), may explain its
enhanced electrophoretic mobility. Using this assay, several
chemical libraries, amounting to 1,100 compounds of different
natures, were screened. We reasoned that the greatest chances
of finding an inhibitor would be among derivatives from chemicalstructures with proven affinity toward kinases, so we screened
the extended validation library of Vichem’s Nested Chemical
Library based on core structures of known, validated kinase
inhibitors. We tested 650 compounds, including pyrazolo-pyrim-
idines, 2,6-phenyl-pyrimidines, and indanones. Therein, we
identified 25 compounds, for example, #2 (Figure 1A), which in-
hibited epidermal growth factor (EGF)-induced ERK dimerization
as a consequence of inhibiting ERK phosphorylation. Two other
compounds, #1 and #3, inhibited ERK dimerization without
affecting its phosphorylation; #3 was the water-soluble 3-aryli-
dene-2-oxindole derivative DEL-22379 (Figure 1B).
Further validation for DEL-22379 as an ERK dimerization inhib-
itor in vivo was obtained using SDS-PAGE electrophoresis (Phi-
lipova and Whitaker, 2005) for lysates from HEK293 cells, in
which ERK dimerization stimulated by EGF was abolished by
treatment with the molecule (Figure 1C). Also in these cells,
DEL-22379 abolished EGF-induced co-immunoprecipitation of
ectopic ERK2 molecules tagged with hemagglutinin (HA) or
FLAG epitopes, with an estimated half-maximal inhibitory con-
centration (IC50) of 0.5 mM (Figure 1D). In both assays, the abil-
ity of DEL-22379 to disrupt ERK dimerization was not related to
ERK phosphorylation, which was unaffected by the compound.
To visualize how DEL-23379 affected ERK dimerization in live
cells, we performed proximity ligation assays (PLAs). ERK dimer-
ization was more prominent at the cytoplasm of EGF-stimulated
HeLa cells, in agreement with our previous studies (Casar et al.,
2008). Contrarily, ERK dimers were undetectable in cells previ-
ously treated with DEL-22379 (Figures 1E and S1D). The ERK
dimer interface is formed from a nonhelical leucine zipper (Wils-
bacher et al., 2006). Heterodimerization of the transcription fac-
tors MYC and MAX takes place by a similar interaction (Lu¨scher
and Larsson, 1999). However, MYC/MAX heterodimerization
was unaffected by DEL-22379 (Figure S1E). This demonstrated
that DEL-22379 generally does not interfere with all protein-
protein interactions of the leucine zipper type.
It was important to determine whether DEL-22379 prevented
the formation of ERK dimers in vitro. To this end, ERK2 purified
from bacteria was phosphorylated in vitro by purified, activated
MEK1 DN EE in the presence of increasing concentrations of the
compound. ERK2 dimerization was progressively inhibited with
an IC50 of 0.5 mM (Figure S1F), without alterations in ERK2
phosphorylation (Figure 1F). However, DEL-22379 could not
disrupt preformed dimers (Figure S1G). To test whether DEL-
22379 affected ERK kinase activity, we performed in vitro kinase
assays, using myelin basic protein (MBP) as a substrate for ERK
immunoprecipitated from EGF-stimulated cells pretreated with
DEL-22379 or the MEK inhibitor U0126 as a control. It was found
that ERKkinase activitywas unaltered byDEL-22379 (Figure 1G).
Overall, these data demonstrate that DEL-22379 is a bona fide
inhibitor of ERK dimerization, but it does not affect ERK phos-
phorylation or ERK kinase activity.
It was of interest to know how DEL-22379 docked onto ERK.
Therefore, we performed in silico docking studies, using the
available structural data on ERK2 (Canagarajah et al., 1997;Wils-
bacher et al., 2006) to generate a feasible docking model. It was
not possible to situate the ligand on the dimerization surface. In
contrast, it docked on the cleft defined by residues Pro 174, Asp
175, His 176, Asp 177, Phe 181, and Phe 329 (Figure 2A; Figures
S2A–S2D); His 176 was particularly relevant, because chargeCancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc. 171
Figure 1. Identification and Validation of
DEL-22379 as an ERK Dimerization Inhibitor
(A) Native PAGE of compounds that inhibit ERK
dimerization without affecting ERK phosphoryla-
tion. Starved HEK293 cells were treated with the
inhibitors or U0126 as the positive control (10 mM
for 30 min) and stimulated with EGF (100 ng/ml
for 10 min). St, starved cells.
(B) Structure of DEL-22379.
(C) ERK dimerization analyzed by SDS-PAGE in
lysates from HEK293 cells treated with EGF and
DEL-22379.
(D) Concentration-dependent effect of DEL-22379
on the co-immunoprecipitation of HA- and FLAG-
tagged ERK2 in HEK293 cells.
(E) Effects of DEL-22379 on dimerization of HA-
and FLAG-tagged ERK2 in live HeLa cells deter-
mined by PLA. Scale bars, 10 mm.
(F) DEL-22379 effect on ERK2 dimerization in vitro.
Purified ERK2 was incubated with activated GST-
MEK DN EE plus increasing concentrations of
DEL-23379.
(G) DEL-22379 effect on ERK2 kinase activity,
determined in ERK2 immunoprecipitates using
MBP as a substrate.
See also Figure S1 and Table S1.repulsion at this position is sufficient to disrupt ERK2 dimeriza-
tion (Wilsbacher et al., 2006). This approach suggested that
DEL-22379 bound to ERK2 at a groove within the dimerization
interface, in agreement with its inhibitory effect on the formation
of ERK2 homodimers. In order to validate experimentally this
theoretical docking site, we examined DEL-22379 binding to
ERK2 using microscale thermophoresis. DEL-22379 readily
bound to ERK2 with a Kd estimated in the low micromolar range,
though binding was detectable even at low nanomolar concen-
trations. Contrarily, binding was impaired to different extents
for the ERK2 mutants D175A, H176L, F181A, and F239A, in
which the putative binding site had been altered (Figure 2B),
thereby verifying DEL-22379 docking at the in silico predicted
site. These results demonstrated that DEL-22379 docked onto
ERK2 within the dimerization interface, thereby explaining the
mechanism whereby this compound interferes with the forma-
tion of ERK dimers.
We had previously demonstrated that ERKdimers play a role in
ERKs extranuclear, but not nuclear, signaling. Using an ERK2
mutant H176E, L4A (Khokhlatchev et al., 1998) (HL hereafter)172 Cancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc.that functions in a dominant inhibitory
fashion, impeding ERK dimerization, we
had shown that preventing dimerization
diminished ERK cytoplasmic signaling
but enhanced its nuclear functions (Casar
et al., 2008). Conceivably, DEL-22379
should behave similarly. Indeed, treating
HEK293 cells with DEL-22379 prevented
the phosphorylation of the cytoplasmic ki-
nase RSK1 induced by EGF treatment
(Figure 2C) while enhancing the transacti-
vation of the transcription factor ELK (Fig-
ure 2D) to levels similar to those detectedin cells expressing ERK2 HL. DEL-22379-induced upregulation
in ERK nuclear activity was further confirmed by the enhanced
phosphorylation of the transcription factors ELK, FOS, and
MYC, but not JUN, which is not an ERK substrate (Figure 2E).
Thus, the small molecule inhibitor mirrored the effect observed
whenERKdimerizationwas impededbygeneticmeans,behaving
as a specific blocker of ERK extranuclear signals. As such, we
used RSK1 phosphorylation as a readout to compare the inhibi-
tory potentials of DEL-22379 and of SCH-772984, a recently
described inhibitor of ERKkinase activity (Morris et al., 2013). Pre-
treating cells with either compound inhibited EGF-stimulated
RSK1 phosphorylation, with estimated IC50 values of 500 nM
for both (Figure 2F). These data demonstrated that impeding
ERKdimerization is as effective as inhibiting ERKcatalytic activity
to block biochemical effects elicited by ERK at the cytoplasm.
DEL-22379 Inhibits Growth of Tumor Cells Harboring
RAS-ERK Pathway Oncogenes
Next, we investigated the biological effects of DEL-22379
on tumor cells in culture. We monitored a panel of human cell
Figure 2. Effects of DEL-22379 on ERK
Activity
(A) Docking of DEL-22379 on ERK dimerization
interface as determined in silico.
(B) Binding of DEL-22379 to purified ERK2, WT or
mutants within the binding groove, was evaluated
by microscale thermophoresis. Data show the
average ± SEM from two independent experi-
ments.
(C and D) DEL-22379 effects on ERK cytoplasmic
and nuclear functions. RSK1 phosphorylation (C)
and ELK transactivation (D) in HEK293 cells
treated with DEL-22379 (10 mM for 30 min) or
transfected with ERK2HL and then stimulatedwith
EGF (100 ng/ml for 10 min). Data show the
average ± SEM from three independent experi-
ments. *p < 0.05 by unpaired t test.
(E) Effects of DEL-22379 on the phosphorylation of
transcription factor substrates of ERK.
(F) Comparison of RSK1 phosphorylation inhibition
by DEL-22379 and SCH-772984. (E) and (F) were
assayed in EGF-stimulated HEK293 cells previ-
ously treated for 30 min with increasing concen-
trations of the indicated compounds.
See also Figure S2.lines harboring mutant BRAF (V600E) or RAS (Q61L or G12V)
from tumor types in which these mutations are prominent:
melanoma (BRAF 50%; NRAS 15%) and colorectal cancer
(BRAF 20%; KRAS 35%) (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). In these, we compared the
cytostatic effects of DEL-22379 to those of the MEK inhibitor
PD-0325901 (Montagut and Settleman, 2009) and the ERK ki-
nase inhibitor SCH-772984 (Morris et al., 2013), as reflected by
their half-maximal growth inhibitory concentrations (GI50). It
was found that cell lines harboring mutant BRAF were the
most sensitive to the three compounds. In comparison, wild-
type (WT) cell lines for BRAF and RAS were the most resistant,
and RAS mutant cells exhibited a range of sensitivities (Fig-
ure 3A). In cells showing different oncogenic genotypes, distinct
sensitivity to DEL-22379 could not be attributed to variations on
its effects on dimerization, because the molecule displayed
similar dimerization- and cytoplasmic signaling-inhibitory dose
responses (IC50 of 150–400 nM) regardless of the genotype (Fig-
ure 3B). To investigate the mechanism whereby the ERK dimer-Cancer Cell 28, 170–182ization inhibitor was affecting cellular
viability, we analyzed its potential to
induce apoptosis. It was significantly
induced upon treatment with DEL-22379
in cell lines harboring oncogenic RAS or
BRAF. However, in tumor cells devoid of
such lesions, the apoptotic effects of the
compound were attenuated (Figures 3C
and 3D), similar to what has been shown
for MEK and ERK kinase inhibitors (Morris
et al., 2013; Solit et al., 2006), suggesting
that the survival of these cells is largely in-
dependent of RAS-ERK signals. Thus,
notwithstanding the differences in their
dosages, quite expected when com-paring pharmacologically optimized molecules like PD-
0325901 and SCH-772984 to a ‘‘first hit’’ compound such as
DEL-22379, these results demonstrate that MEK classical inhib-
itors, ERK kinase inhibitors, and ERK dimerization inhibitors
exhibit similar therapeutic indexes with respect to the RAS/
BRAF oncogenic signature, consistent with their mechanism of
action affecting the same signaling pathway.
Noticeably, in cell lines with oncogenic BRAF or RAS, DEL-
22379 GI50 values largely correlated with the ERK monomer-
to-dimer ratio (Figure 4A), indicating a greater sensitivity to
DEL-22379 in those cell lines where ERK dimerization was
more prominent. It was of interest to gain an insight into what
governed the degree of ERK dimerization. Because dimerization
occurs mainly in the cytoplasm (Casar et al., 2008), we reasoned
that factors regulating ERK nucleo- and cytoplasmic distribution
could affect its dimerization. Accordingly, we found that the
expression of PEA15, a protein that retains ERK at the cytoplasm
(Formstecher et al., 2001), correlated with the degree of ERK
dimerization present in BRAF mutant cell lines exhibiting similar, August 10, 2015 ª2015 Elsevier Inc. 173
Figure 3. Evaluation of DEL-22379 Anti-
proliferative Effects in Tumor Cells
(A) GI50 values for the indicated compounds in the
indicated cell lines. Data show the average from
five independent experiments.
(B) ERK dimerization inhibition by increasing con-
centrations (0.1–10 mM) of DEL-22379 in the indi-
cated cell lines.
(C) Induction of apoptosis by DEL-22379 in the
indicated tumor cell lines. Cells were treated with
10 mM DEL-22379 for 12 hr, and apoptosis was
evaluated by Caspase-Glo 3/7 luminogenic assay.
Data show the average ± SEM from five indepen-
dent experiments. n.s, p > 0.05; *p < 0.05; ***p <
0.005 by unpaired t test; RLU, relative light units.
(D) As in (C), apoptosis was determined bywestern
blotting for caspase 3 (C 3). The pro- and cleaved
(active) forms of C 3 are indicated.ERK phosphorylation levels (Figure 4B). Short hairpin RNA
(shRNA)-mediated downregulation of PEA15 in A375 cells,
harboring a high amount of dimeric ERK, markedly reduced
the degree of ERK dimerization. Conversely, PEA15 overexpres-
sion in SW1417 cells, which displayed low ERK dimerization
levels, resulted in a substantial increase on ERK dimers. In every
case, enhanced dimerization resulted in potentiation of cyto-
plasmic signals, while attenuated dimerization favored nuclear
signaling (Figure 4C).
In A375 cells, downregulation of PEA15 induced apoptosis
(Figure 4D), probably as a consequence of the drop on the levels
of ERK dimers, thereby resembling the effect of DEL-22379.
Remarkably, the surviving cells, with reduced ERK dimerization
levels, exhibited an augmented resistance to DEL-22379
compared to parental cells (Figure 4E). Conversely, in SW1417
cells, PEA15 overexpression, and the subsequent increment
on ERK dimerization, increased their sensitivity to DEL-22379
(Figures 4E and 4F). These results show that PEA15 can mark-174 Cancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc.edly influence ERK dimerization and add
further support to the notion that sensi-
tivity to DEL-22379 in RAS-ERK pathway
mutant cells is dictated by the levels of
ERK dimerization.
DEL-22379 Prevents Tumor
Growth and Metastasis in Animals
In light of the data obtained in cell cul-
tures, we evaluated the anti-tumorigenic
effects of the dimerization inhibitor in
animal models. Prior to this, we analyzed
DEL-22379 toxicity in mice. To determine
a tolerable dose range for in vivo studies,
mice were administered intra-peritoneal
injections of DEL-22379 at doses ranging
from 100 to 12 mg/kg (Figure S3A). The
maximum tolerated dose was estimated
at 15 mg/kg every 12 hr, defined as the
highest dose that did not cause (1) alter-
ations in motor coordination, activity,
and muscular tone (Figure S3B) or (2)loss in body weightR 20% (Figure S3C) or overt toxicity signs,
such as abnormal behaviors, poor grooming, hunched posture,
abnormal urine stains, or dehydration. In addition, the compound
did not evoke toxicity in hematopoietic lineages (Table S2). In the
liver, while some focal necrotic and steatotic lesions were
evident (Figures S3D and S3E), the biochemical serum parame-
ters for hepatocellular and cholestatic function were unaltered,
indicating no gross liver malfunction (Table S3). In intestinal
epithelia, shorter villi and mucus overproduction (Figures S3F
and S3G) revealed some toxicity. Despite this, no diarrhea or
overt signs of intestinal malfunction were evident. Thus, DEL-
22379 toxicity should be considered mild. DEL-22379 pharma-
cokinetics was assessed in mice over a 72-hr time course
following exposure to either single or multiple doses. Despite
its short half-life in vivo, with a nearly complete clearance from
plasma after the 12-hr dosing period, DEL-22379 plasma
concentration reached a Cmax of 1 mM at 1 hr, well over the
IC50 values required to exert in vitro cytostatic effects in most
Figure 4. Regulation of ERK Dimerization
by PEA15
(A) ERKmonomers-to-dimers ratio in the indicated
cell lines, and correlations with their respective
GI50 values.
(B) Correlation of ERK dimerization levels with
PEA15 levels in the indicated cell lines. Figures
show the monomers-to-dimers ratio and PEA15
levels relative to the cell line with the highest levels.
(C) Impact of PEA15 on ERK dimerization and ERK
nucleo- and cytoplasmic signals. The indicated
cell lines were transfected with anti-PEA15 shRNA
or FLAG-PEA15 (1 mg). Figures show the mono-
mers-to-dimers ratio.
(D) Caspase 3 activation in A375 cells in response
to downregulation of PEA15.
(E) Correlation between PEA15 levels and DEL-
22379-induced caspase 3 activation in SW1417
cells. Where indicated, cells were treated with
1 mM of the compound for 12 hr, and caspase 3
activity was evaluated by Caspase-Glo 3/7 assay.
Data show the average ± SEM from five indepen-
dent experiments. *p < 0.05 by unpaired t test;
RLU, relative light units.
(F) Correlation between PEA15 levels and DEL-
22379 GI50 values. Data show the average from
five independent experiments.RAS-ERK pathway mutant cell lines, a concentration sustained
over 8 hr (Figure S3H).
To test DEL-22379 antitumor effects, some of the aforemen-
tioned cell lines were xenografted into nude mice, and tumor
growth was monitored after intra-peritoneal administration of
the compound at 15 mg/kg. At such a dose, inhibition of ERK
dimerization was evident in liver extracts (Figure 5A) and in xen-
ografted tumors (Figure 5B). It was found that DEL-22379 mark-
edly inhibited tumor progression for A375 cells (BRAF mutant)
(Figures 5C and 5D). However, it failed to prevent the formation
of tumors in mice injected with CHL cells (WT/WT) (Figures 5D
and S3I). Surprisingly, tumors driven by activated RAS, like
those derived fromHCT116 cells, exhibited a pronounced sensi-
tivity to DEL-22379 (Figures 5D and S3I), in contrast to their
behavior in culture (Figure 3A). Interestingly, the proportion of
ERK in dimeric form was much greater in HCT116-derived tu-
mors than in HCT116 cells growing on plastic. Accordingly, cellsCancer Cell 28, 170–182from HCT116-derived tumors exhibited
upregulated PEA15 levels and enhanced
cytoplasmic signaling (Figure 5E). This
suggested that for HCT116 cells, tumori-
genesis in vivo had greater requirements
for ERK dimerization than for proliferation
in culture.
In light of DEL-22379 antitumor proper-
ties, we tested DEL-22379 efficiency
in vivo using a colorectal cancer patient-
derived xenograft (PDX) model that
faithfully recapitulates the human disease
(Puig et al., 2013). To this end, cells from
BRAF mutant human colorectal adeno-
carcinoma were isolated as described
(Puig et al., 2013) and injected subcuta-neously into non-obese diabetic, severe combined immunodefi-
ciency (NOD-SCID) mice. After detectable engraftment of the
tumors (diameter > 0.4 mm), the evolution of the tumor mass
wasmonitored in control and DEL-22379-treated mice. Remark-
ably, treatment with the dimerization inhibitor significantly
mitigated growth of the BRAF mutant PDX (Figure 5F). Histo-
pathological analyses of the tumors at the endpoint revealed
that DEL-22379 caused extensive mucinous differentiation and
cell death (Figure S3J), in agreement with those effects observed
in both in vitro cultures and mouse xenografts using cancer cell
lines.
To further substantiate our findings, we assayed whether DEL-
22379 could revert the oncogenic process after the primary tu-
mor had developed andmetastatic dissemination was apparent.
We utilized chicken embryo chorioallantoic membrane (CAM)
xenografts (Deryugina and Quigley, 2008), which are especially
suited for such analyses. Tumor cells were grafted on the, August 10, 2015 ª2015 Elsevier Inc. 175
Figure 5. Antitumor Effects of DEL-22379 in Mice
(A and B) ERK dimerization in liver extracts (A) or tumors derived fromHCT116 cells (B) frommice treatedwith DEL-22379 (15mg/kg every 12 hr for 15 days). EGF-
stimulated HEK293 cells are shown as the positive control. Ve, vehicle.
(C) Effects of DEL-22379 on the growth of tumors derived from A375 cells after 15 days.
(D) Correlation between DEL-22379 effects on tumor growth in mice and the mutational status of the xenografted cell lines.
(E) Comparison of the ERK monomers-to-dimers ratio in HCT116 cells derived from tumors in mice (tum) or growing on plastic plates (plas). In (D) and (E), data
show the average ± SEM from five independent experiments. n.s., p > 0.05; *p < 0.05; ***p < 0.005 by unpaired t test.
(F) Effects of DEL-22379 on tumor growth in a BRAF mutant colorectal cancer PDX model. The longitudinal tumor growth plot shows the fold change of tumor
volume for tumors formed in mice (n = 5–8) after 21 days of treatment. Error bars represent the ±SD p value by unpaired t test.
See also Figure S3 and Tables S2 and S3.
176 Cancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc.
Figure 6. Effects of DEL-22379 on Tumor
Progression and Metastasis
(A) DEL-22379 effects on tumor size, tumor cell
intravasation, and liver metastases of the cell lines
with indicated mutational status xenografted on
chicken CAMs and allowed to progress for 5 days
before drug administration (10 mM every 12 hr).
Data show the average ± SEM from three inde-
pendent experiments. n.s., p > 0.05; *p < 0.05;
**p < 0.01; ***p < 0.005 by unpaired t test.
(B) Tumor regression in a BRAF mutant colorectal
cancer orthotopic PDX model, treated with DEL-
22379 (15 mg/kg every 12 hr) for 30 days. Repre-
sentative pictures of immunofluorescence and
confocal microscopy of sections from xenografts
growing in the cecum wall. Ki67 and caspase 3
(C 3) expressions are shown in green; b-catenin
(red) identifies cancer cells. Scale bar, 200 mm.
Right panels: Column scatter plot for Ki67 or C 3
levels measured by immunofluorescence and
confocal microscopy. Lines show mean values,
p values by unpaired t test.
See also Figure S4.embryo’s CAM and allowed to expand for 5 days, resulting in
extensive intravasation and liver metastasis. At this point, DEL-
22379 was added and the evolution of the primary tumor and
metastases was monitored. After 5 days, for A375 (BRAF
mutant) and HCT116 (KRAS mutant) cells, a marked regression
of the primary tumor size, as a consequence of prominent
apoptosis (Figure S4), and drops in the number of cells in circu-
lation and invading the liver were evident. Conversely, tumor pro-
gression in Colo320 (WT/WT) cells was undeterred (Figure 6A).
Further evidence on the ability of DEL-22379 to induce regres-
sion of advanced tumors was obtained from an orthotopic PDX
model, in which BRAF mutant human colorectal adenocarci-
noma cells were grafted in the cecum of NOD-SCID mice and
allowed to progress for a month. At that point, DEL-22379 was
administered for 30 days, and its antineoplastic effects wereCancer Cell 28, 170–182assessed. Treatment with DEL-22379 re-
sulted in a pronounced arrest of tumor
cell proliferation, as demonstrated by
reduced Ki67 staining, accompanied by
massive apoptosis, which was revealed
by augmented cleaved caspase 3 levels
(Figure 6B). Overall, these results demon-
strated that targeting ERK dimerization
pharmacologically prevented tumorigen-
esis at various stages when driven by
RAS-ERK pathway oncogenes.
DEL-22379 Antineoplastic Effects
Are Specifically Based upon Its
Ability to Impede ERK Dimerization
In the course of the experiments dealing
with CAM xenografts, we found that PD-
0325901 and DEL-22379 reduced the
growth of A375-derived tumors to similar
extents (Figure 7A). However, PD-
0325901 treatment resulted in a chickenembryo death rate of 50%, probably as a consequence of
potent ERK signaling suppression (Figure S5A). Conversely, em-
bryos were unaffected by DEL-22379 (Figure 7A). Surprisingly,
while ERK dimerization was apparent in the xenografted tumors,
and markedly inhibited in those treated with DEL-22379, we
could not detect ERK dimerization in the corresponding chick
embryo livers in any case (Figure 7B), unlike what was previously
observed in mouse livers (Figure 5A). Expectedly, phospho-ERK
analyses in livers showed that Gallus gallus does not express
ERK1 (Lefloch et al., 2008). The absence of ERK dimerization
in chickens prompted us to interrogate other species across
the evolutionary scale. We found that dimerization was also
absent in ERK orthologs from amphibians (Xenopus laevis) and
fish (Danio rerio) and only appeared in mammals: mice, dogs,
and humans (Figure 7C). To further substantiate this point, we, August 10, 2015 ª2015 Elsevier Inc. 177
Figure 7. Association of DEL-22379 Anti-
tumor Effects with Inhibition of ERK Dimer-
ization
(A) Effects of DEL-22379 and PD-0325901 (10 mM
each) on tumor growth (left) and chick embryo
viability (right). Data show the average ± SEM from
three independent experiments. n.s., p > 0.05; *p <
0.05; **p < 0.01 by unpaired t test.
(B) Effects of DEL-22379 on ERK dimerization in
embryo livers (upper panels) and in A375-deriver
tumors (lower panels). EGF-stimulated HEK293
cells are show as the control.
(C) Analysis of ERK dimerization in different animal
species.
(D) HA- or FLAG-tagged versions of human (Hs)
and zebrafish (Dr) ERK were co-transfected (1 mg
each) in the indicated cell lines and tested for co-
immunoprecipitation upon EGF stimulation
(100 ng/ml for 10 min). St, starved cells. Lower
panel: ERK phosphorylation in the indicated cell
lines without or with EGF treatment.
(E) Melanin content and melanocytes numbers in
WT and HRASV12 zebrafish larvae, treated with
DEL-22379 or MEK inhibitors. Data show the
average ± SEM. *p < 0.05 by ANOVA.
(F) DEL-22379 effects in the presence of ERK2
F181A. Left: dimerization of ERK2 F181A in vitro
when incubated with activated GST-MEK DN EE.
Right: DEL-22379 GI50 values in A375 cells over-
expressing ERK2 F181A relative to those of
parental cells. Data show the average ± SEM from
three independent experiments. n.s., p > 0.05;
***p < 0.001.
See also Figure S5 and Tables S4 and S5.co-expressed FLAG- and HA-tagged versions of zebrafish and
human ERK2 in human (HEK293) and zebrafish (Pac-1) cells.
Upon EGF stimulation, humanHA-ERK2 co-immunoprecipitated
with its FLAG-tagged version in both cell types, but we could not
detect zebrafish HA-ERK2 associated with its FLAG-tagged
form in any case (Figure 7D). These results ascertained that ze-
brafish ERK2 does not dimerize and suggest that such inability
resides on the zebrafish protein, not on the cellular context.
This unexpected finding offered an invaluable scenario
for testing DEL-22379 antitumor effects in the absence of
ERK dimerization. Transgenic zebrafish expressing oncogenic
RASV12 in melanocytes develop melanomas, with neoplasia
detectable at early larval stages (Michailidou et al., 2009) (Fig-
ures S5B–S5D). In these animals, melanoma development was
characterized by increments in both melanocyte numbers and
melanin contents with respect to WT fish. It was found that mel-
anoma progression was prevented by treatment with the MEK
inhibitors PD-184352 and SL-327. In contrast, DEL-22379 was178 Cancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc.ineffective in stopping neoplasia expan-
sion up to the point when animals had
to be sacrificed in accordance with hu-
mane endpoint guidelines (Figures 7E,
S5E, and S5F).
These data suggested that DEL-22379
antineoplastic properties could be specif-
ically attributed to the ability of DEL-22379 to prevent ERK dimerization. To further substantiate this
point, we used ERK2 mutant F181A. This form is defective for
binding to DEL-22379 (Figure 2B) yet retains its ability to dimerize
(Figure 7F). When overexpressed in A375 cells, F181A conferred
these cells with remarkable resistance to the inhibitor cytostatic
effects, as shown by a dramatically increase in GI50 (Figure 7F).
These results added support to the notion that in the absence of
an ERK amenable to being targeted, DEL-22379 antitumor
capacity is lost.
We investigated further DEL-22379 potential off-target effects
by profiling the ability of DEL-22379 to inhibit a panel of 300 ki-
nases. Noticeably, DEL-22379 displayed remarkable inactivity:
the vast majority of the kinases tested were minimally affected,
and only six kinases showed inhibition over 50% (Table S4). Of
these, TRK-A, TRK-B, SNF1LK2, andMYLK2 are specifically ex-
pressed in tissues irrelevant to this study. STK17A is a pro-
apoptotic kinase whose inhibition would potentiate, not inhibit,
tumorigenesis (Mao et al., 2011). PDGFr-b expression was found
Figure 8. DEL-22379 Response to Classical Drug-Resistance Mech-
anisms
(A) Cell numbers of A375 cells, parental or overexpressing NRASV12, treated
with DEL-22379 (1 mM) or the BRAF inhibitor PLX-4032 (10 mM) for the indi-
cated periods of time.
(B) As in (A), cell numbers for A375 cells overexpressing the indicated MEK1
allosteric site mutants, treated with DEL-22379 or the MEK inhibitor PD-
0325901 (10 mM).
(C) HT-29 cells (BRAF mutant), parental or overexpressing BRAFV600E, were
treated with DEL-22379 or with PD-184352. In all cases, data show the
average ± SEM from three independent experiments. *p < 0.05; **p < 0.01 by
unpaired t test.to be low or undetectable in the colorectal and melanoma cell
lines used in our experiments (Nazarian et al., 2010) (Figure S5G).
In these, we could not detect any relationship between PDGFr-b
expression and sensitivity to DEL-22379.
Finally, we compared the transcriptional alterations evoked by
an inhibitor that totally suppresses ERK signaling, such as the
ERK kinase inhibitor SCH-772984, to those elicited by DEL-
22379 that only suppress the ERK cytoplasmic signal. For this,
A375 cells were treated with the aforementioned inhibitors for
2 hr, and the resulting transcriptomes were analyzed by RNA
sequencing. SCH-772984 altered the expression of 505 genes.
DEL-22379 altered the expression of only 34 genes, all of
which were downregulated, including genes encoding proteins
involved mainly in regulation of ERK activity (DUSP6, SPRTY2,and SPRTY4), survival (IER3, MYC, DAPK3, SHARPIN, and
PARP10), vesicle trafficking (RAB3, DPP7, and FASN), blood
vessel morphogenesis (APOE, IL8, and ZFP36L1), and nucleo-
tide phosphate binding (CHTF18, GALK1, NUBP2, and
NAPRT1). Noticeably, all but one (ZFP36L1) were in common
with SCH-772984 (Table S5, the entire dataset is available at
GSE68230). Altogether, the data mentioned earlier strongly indi-
cate that the DEL-22379 therapeutic effect relies on its inhibition
of ERK dimerization, not on unidentified off-target effects.
Inhibition of Tumor Cell Growth by DEL-22379 Is
Unaffected by Drug-Resistance Mechanisms
Tumor cells acquire resistance to MEK and BRAF inhibitors by
diverse molecular mechanisms (Little et al., 2013), so it was
important to determine whether such processes affected DEL-
22379. In melanomas, upregulation of NRAS confers resistance
to BRAF inhibitors in BRAFmutant tumors (Nazarian et al., 2010).
In agreement, we found that overexpression of NRASV12 in
A375 cells made them refractory to the anti-proliferative effect
of the BRAF inhibitor PLX-4032. Contrarily, these cells remained
sensitive to inhibition by DEL-22379 (Figure 8A). Similarly, point
mutations that arise in the allosteric drug-binding pocket of
MEK1 (Emery et al., 2009) result in melanoma resistance to
MEK inhibitors. We simulated such situation by the overexpres-
sion of MEK1 mutants L115P and I103N (Emery et al., 2009) in
A375 cells, which made them insensitive to proliferative arrest
by the MEK inhibitor PD-0325901, but this could not revert
growth inhibition in response to DEL-22379 treatment (Fig-
ure 8B). Likewise, amplification of oncogenic BRAF in colorectal
cancer underpins acquired resistance to drugs inhibiting MEK
(Little et al., 2011). As such, we found that overexpression of
BRAFV600E in HT29 cells made them unresponsive to treatment
with PD-0325901, while they remained entirely sensitive to DEL-
22379 (Figure 8C). Overall, these results demonstrated that the
cytostatic effect of the ERK dimerization inhibitor DEL-22379 is
indifferent to drug-resistance mechanisms that hamper classical
RAS-ERK pathway inhibitors.
DISCUSSION
In our search for mechanisms of action to be exploited as thera-
peutic targets for neoplasia driven by RAS-ERK pathway onco-
genes, we have focused on ERK dimerization.We had previously
unveiled this regulatory protein-protein interaction as a potential
target for antitumor drugs, since preventing it by molecular
biology approaches forestalled tumor progression for cell lines
harboring oncogenic KRAS (Casar et al., 2008). In order to
screen for compounds capable of inhibiting ERK dimerization,
we set up a method for detecting ERK dimerization using native
gel electrophoresis and extensively validated it. Using this tech-
nique, we identified the 3-arylidene-2-oxindole derivative DEL-
22379. By diverse methodologies we verified that DEL-22379
is a bona fide ERK dimerization inhibitor that does not alter
ERK phosphorylation levels and, consequently, does not affect
ERK kinase activity. We identified the DEL-22379 binding site
on ERK2 in a cleft within its dimerization interface, close to res-
idues that play essential roles in the dimerization process, such
as His 176 (Wilsbacher et al., 2006). Thus, we can speculate
that DEL-22379 inhibits ERK dimerization by docking onto theCancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc. 179
dimerization interface, thereby preventing the interaction be-
tween two ERK molecules taking place.
We have extensively studied DEL-22379 antitumor properties
in diverse models for RAS-ERK pathway-driven neoplasia. It has
been demonstrated that the anti-proliferative efficacy of kinase
inhibitors aimed at RAS-ERK signals depends on the driver
oncogenic lesion (Bollag et al., 2010; Morris et al., 2013; Pouli-
kakos et al., 2010; Solit et al., 2006). We found that DEL-
22379 exhibits the greatest cytostatic potential against tumor
cell lines harboring mutant BRAF; it has variable effects in those
with oncogenic RAS, and it is largely ineffective in cell lines
devoid of RAS-ERK pathway mutations. Thus, DEL-22379 fully
resembles MEK (Solit et al., 2006) and ERK (Morris et al.,
2013) kinase inhibitors. These data suggest that the DEL-
22379 therapeutic effect is specifically mediated through its
impact on ERK by preventing its dimerization. This notion is
further endorsed by our results showing that the sensitivity of
tumor cell lines to DEL-22379 correlates greatly with their con-
tent of ERK in dimeric form. ERK dimerization is known to
depend on ERK phosphorylation (Khokhlatchev et al., 1998)
and to occur in the presence of cytoplasmic components (Phili-
pova and Whitaker, 2005), such as scaffold proteins (Casar
et al., 2008). Adding to this, we now unveil PEA15 as a promoter
of ERK dimerization, probably by retaining ERK at the cyto-
plasm, thereby facilitating its interaction with scaffolds therein.
Therefore, differences in these factors, and probably in others
hitherto unidentified, among distinct cellular contexts may
alter the degree of ERK dimerization and, consequently, the
response to DEL-22379.
More importantly, our data demonstrate that DEL-22379 is
effective as an antitumor agent in animal xenograft models for
RAS-ERK pathway-driven carcinogenesis, with low toxicity at
therapeutic doses. In this realm, DEL-22379 elicits a pronounced
apoptotic response in xenografts frommelanoma and colorectal
cancer cell lines harboring mutantBRAF andRAS. By this mech-
anism, DEL-22379 is capable not only of preventing the growth
of nascent tumors but also of reducing primary tumor mass
andmetastatic dissemination in tumors allowed to progress prior
to treatment with the compound. Of particular importance are
our data showing that DEL-22379 is effective in preclinical ortho-
topic PDX models for BRAF mutant colorectal cancer. At pre-
sent, there is no effective, lasting drug therapy against this
type of colorectal cancer (Holderfield et al., 2014). Therefore,
ERK dimerization inhibitors may open a promising venue for
future therapies.
By different means, we have demonstrated that DEL-22379
antineoplastic effects are specifically based on its properties
as an inhibitor of ERK dimerization and are not a consequence
of unidentified off-target effects. Importantly, we show that
DEL-22379 is ineffective for preventing melanoma progression
in zebrafish, a species in which ERK does not form dimers. The
absence of ERK dimerization in some species is a surprising
finding currently under study in our laboratory. Interestingly, we
show that DEL-22379 alters the expression of only 34 genes,
all but one in common with those affected by the ERK kinase in-
hibitor SCH-772984, further indicating its specificity for ERK
signaling. This result also illustrates that DEL-22379 has few
transcriptional effects, in full agreement with its function as an in-
hibitor of ERK extranuclear signals, and that its pro-apoptotic180 Cancer Cell 28, 170–182, August 10, 2015 ª2015 Elsevier Inc.functions must be exerted largely by transcription-independent
mechanisms. Moreover, this result implies that the increased
phosphorylation of exchange factors such as ELK, FOS, and
MYC observed upon DEL-22379 treatment would have few tran-
scriptional consequences, probably because ERK-mediated
transcriptional output would be at its maximum prior to the
nuclear influx of additional ERK monomers resulting from
the disruption of ERK dimers by DEL-22379. Interestingly, it
has been reported that knockdown of the scaffold protein
KSR1, thereby downregulating ERK cytoplasmic signaling, im-
pairs MYC oncogenic function and enhances MYC-mediated
apoptosis (Gramling and Eischen, 2012). It is tempting to specu-
late that enhanced MYC phosphorylation following DEL-22379
treatment serves this purpose.
We had previously described ERK dimers as playing an essen-
tial role in the regulation of ERK cytoplasmic signals but not nu-
clear ones and how inhibiting the ERK extranuclear component
was sufficient to forestall cellular transformation and tumor pro-
gression (Casar et al., 2008). DEL-22379 fully recapitulates these
notions. In agreement, melanoma response to the BRAF inhibitor
PLX-4032 correlates with a drop in cytoplasmic, but not nuclear,
ERK activity (Bollag et al., 2010). Thus, our findings show that a
small molecule inhibitor specifically targeting the extranuclear
component of RAS-ERK signals can be as effective as inhibitors
aimed at completely blocking RAS-ERK flux for antineoplastic
intervention.
Overall, we demonstrate that amolecule inhibiting a regulatory
protein-protein interaction such as ERK dimerization can be
effectively used in cancer therapy. Our results endorse recent
findings pointing to other regulatory protein-protein interactions,
such as dimerization of BRAF (Freeman et al., 2013) and ARAF
(Mooz et al., 2014), as potential therapeutic targets in the RAS-
ERK pathway. Indeed, this strategy has proven successful in
other realms. For example, drug-mediated inhibition of the inter-
action between the leukemia-associated proteins RUNX1 and
CBF-b prevented proliferation of leukemic cells (Gorczynski
et al., 2007).
Our findings demonstrate that inhibiting ERK dimerization by a
compound that prevents ERK-ERK interaction evokes antineo-
plastic effects. This opens the possibility that interfering with
other mechanisms involved in ERK dimerization would yield
similar therapeutic outcomes. ERK scaffold proteins serve as
dimerization platforms (Casar et al., 2008). Thus, small mole-
cules aimed at preventing ERK-scaffold interactions could
pose an alternative strategy for inhibiting ERK dimerization and
thereby a therapeutic venue for antineoplastic intervention.
This notion is supported by findings demonstrating that disrup-
tion of scaffold proteins like KSR1 (Lozano et al., 2003) and
IQGAP1 (Jameson et al., 2013) can effectively prevent RAS-
driven tumorigenesis.
In addition, our ERK dimerization inhibitor can overcome
molecular processes that confer resistance to BRAF and MEK
inhibitors. Furthermore, ERK dimerization inhibitors could prove
useful in situations in which ATP-competitive ERK inhibitors fail,
like those cases in which the appearance of ERK mutations
confer resistance to such inhibitors by interfering with drug bind-
ing (Goetz et al., 2014). Thus, these kinds of compounds could
provide efficacious second-wave therapeutics for those cases
in which resistance to classical RAS-ERK pathway inhibitors
emerges. Moreover, it is conceivable that ERK kinase inhibitors
would be insensitive to hypothetical ERK dimerization interface
mutations that would inactivate dimerization inhibitors. There-
fore, both types of ERK inhibitors could replace each other, de-
pending on the resistance mechanism to be treated. In addition,
though purely speculative at this stage, since ERK dimerization
inhibitors can produce a therapeutic effect by just partial sup-
pression of ERK functions, it is possible that they cause fewer
undesired side effects than those therapeutics that suppress
ERK activation completely. Indeed, the mild toxicity exhibited
in mice suggests this effect. Thus, this may open the door for
higher dosages and prolonged treatments, evoking improved
cancer treatments.
EXPERIMENTAL PROCEDURES
Native PAGE for detecting ERK dimers was performed exactly as previously
described (Pinto and Crespo, 2010). Compound screening was performed in
HEK293T cells treated with the potential inhibitors (10 mM) for 30 min before
EGF stimulation. Cellular lysates were tested for ERK dimerization by native
PAGE and p-ERK evaluation of the potential positives.
In vitro ERK dimerizationwas assayed usingGST-MEK1DNEE purified from
bacteria, bound to glutathione sepharose beads, and incubated with 25 mg/ml
of purified His-ERK2 plus increasing concentrations of DEL-22379. Western
blotting, kinase assays, and luciferase assays also performed as described
(Casar et al., 2008). In silico docking of the DEL-22379 compound was carried
out with the modeling tools provided by the OpenEye package (v. 2.1) (http://
www.eyesopen.com).
Tumor cell lines were from our collection or from ATCC. GI50 were
analyzed as described (Solit et al., 2006): cells were plated at a density of
1,000–2,000 cells/well and treated with the drugs for 48 hr, Alamar Blue
(Invitrogen) was added, and the colorimetric change was measured at 570
and 600 nm. GI50 was estimated by nonlinear regression using GraphPad5
Prism Software. Apoptosis was analyzed by evaluating caspase 3 activity,
either by western blotting or using the Caspase-Glo 3/7 luminogenic assay
(Promega).
Cancer cells were xenografted in female, athymic nu/nu mice of 8 weeks of
age as described (Casar et al., 2008). 33106 cells were injected subcutane-
ously in the lateral flank and allowed to develop for 10–15 days before
treatment with DEL-22379 at 15 mg/kg every 12 hr for 2 weeks. PDXs
were performed using patient-derived colorectal cancer cells harboring
BRAFV600E from non-necrotic areas of primary adenocarcinomas from
patients that underwent surgical resection, basically as described (Tenbaum
et al., 2012). Written informed consent was signed by all patients. The project
was approved by the Research Ethics Committee of the Vall d’Hebron Univer-
sity Hospital, Barcelona, Spain (Approval ID: PR(IR)79/2009). Cells were
grafted in both flanks or in the cecum of NOD-SCID mice. DEL-22379 was
administered by intra-peritoneal injection at a concentration of 15mg/kg every
12 hr for 30 days.
Assays to evaluate metastasis in chick embryos were performed as
described (Deryugina and Quigley, 2008). We inoculated 106 tumor cells on
the chorioallantoic membrane and incubated the eggs for 5 days at 38C.
Then, the different drugs were added topically on the upper CAM; treatments
were refreshed every 12 hr. Human cells within chick embryo tissues were de-
tected by real-time Alu PCR.
Carcinogenesis experiments in zebrafish were carried out as described
(Michailidou et al., 2009). Treatments with inhibitors were performed in larvae
at 2 days post-fertilization (dpf). Larvae were incubated in the presence of in-
hibitors for 72 hr, refreshed every 24 hr. At 5 dpf, the experiments were
terminated.
All experiments involving animals were approved by the Animal Care Com-
mittee of the University of Cantabria to verify compliance with the Spanish
(Real Decreto 53/2013) and European Communities Council Directive 2010/
63/UE, ‘‘Protection of Animals Used in Experimental and Other Scientific Pur-
poses.’’ Detailed descriptions of the different protocols are available as Sup-
plemental Experimental Procedures.ACCESSION NUMBERS
The National Center for Biotechnology Information’s Gene Expression
Omnibus database accession number for the microarray datasets is
GSE68230.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.07.001.
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